Regentis Biomaterials (NYSEAMERICAN:RGNT) Shares Down 35.1% – What’s Next?

Shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) fell 35.1% on Tuesday . The company traded as low as $6.10 and last traded at $6.10. 8,239,709 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 15,669,613 shares. The stock had previously closed at $9.40.

Analysts Set New Price Targets

Separately, ThinkEquity raised Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Regentis Biomaterials currently has an average rating of “Strong Buy”.

Regentis Biomaterials Price Performance

The stock’s fifty day moving average price is $2.62.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials as of its most recent SEC filing.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.